Pangea Bio

📍 London, United Kingdom🗓 Founded 2021👥 29 employees💰 Last funded Dec 2025
Pangea Bio is developing novel therapies that directly activate the TrkB receptor, driving neuronal and synaptic plasticity, and neuroprotection. Dysfunction of the BDNF/TrkB pathway is a hallmark of disorders such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s disease, and glaucoma.
8
Total investors
6
Early stage
2
Mid stage
0
Late stage
2021
Founded
Investor geography4 countries
United States
4
Spain
1
Germany
1
United Kingdom
1
Investor activity2022–2025 · investors recorded per year
20225202312024120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Pangea Bio?
Pangea Bio has 8 investors on record on gritt.io, including 6 early-stage backers, 2 mid-stage.
When did Pangea Bio last raise funding?
The most recent investment in Pangea Bio recorded on gritt.io was in December 2025.
When was Pangea Bio founded?
Pangea Bio was founded in 2021.
What industry is Pangea Bio in?
Pangea Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Pangea Bio based?
Pangea Bio is headquartered in London, United Kingdom.